Warning: Last items in stock!
Availability date:
Parvovirus B19 VLP VP1/VP2 Co-Capsid Recombinant ( Parvovirus B19 VLP VP1/VP2 )
Recipient :
* Required fields
or Cancel
Formulation | Parvovirus B19 VLP VP1/VP2 protein solution is supplied in 16mM Sodium phosphate pH-7.4, 120mM NaCl and 20% glycerol. |
Purity | Greater than 80.0% as determined by SDS-PAGE. |
Description | Recombinant Parvovirus B19 VLP VP1/VP2 Co-Capsid produced in SF9 containing B19 capsid proteins VP1 (86,049 Dalton) and VP2 (60,839 Dalton).Parvovirus B19 VLP VP1/VP2 is purified by proprietary chromatographic techniques. |
Protein Background | The B19 virus, usually referred to as parvovirus B19 or sometimes as erythrovirus B19, belongs to the family of parvoviruses, genus erythrovirus. B19 virus causes a childhood rash named fifth disease or erythema infectiosum which is ordinarily known as slapped cheek syndrome. Erythroviruses are members of the Parvoviridae family of small DNA viruses. The B19 virus is a non-enveloped, icosahedral virus which contains a single-stranded linear DNA genome. Parvovirus B19 is classified as erythrovirus because of its capability to invade red blood cell precursors in the bone marrow. This virus is mainly spread by infected respiratory droplets; though, blood-borne transmission has also been reported. |
Expression host | Sf9 insect cells. |
Reagent Appearance | Sterile Filtered clear solution. |
Stability | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles. |
Protein concentration | Arylesterase 2 can be used directly as a positive control in Western blotting, ELISA, immunoprecipitation and other immunological experiments. The biological activity of this product has not yet been tested. |